Phasefocus release their new Livecyte T-cell killing assay

14 September 2023

Sign up to their upcoming webinar to discover more about the efficacy and cytotoxicity of engineered T-cells in killing target cancers

This revolutionary new assay by Phasefocus addresses key challenges faced by researchers in investigating the efficacy and cytotoxicity of engineered T-cells in killing target cancers. By offering unparalleled insights at the single-cell level, the Livecyte kinetic cytometer empowers researchers to unlock new pathways in cancer therapy development and evaluation.

Register for their upcoming webinar on Tuesday 19 September 2023 9AM BST/4PM BST to learn more by clicking the button at the bottom of the page.

Bridging the gap between in-vitro and in-vivo T-cell therapy performance

Current live cell imaging assays lack the ability to provide comprehensive and accurate insights into the dynamics and history of effector-target cell interactions. Existing solutions focus on population-level analysis and target cell death without exploring the effector interactions leading to death, leaving researchers with limited direct understanding of T-cell efficacy. Consequently, the gap between in-vitro and in-vivo T-cell therapy performance remains a significant challenge.

The lack of precise single-cell data prevents researchers from fully understanding the intricacies of T-cell-target cell interactions, hindering the development of robust and reliable T-cell therapies. The failure of many T-cell therapies in in-vivo models and clinical studies underscores the pressing need for an in-vitro model that accurately recapitulates in-vivo T-cell behaviour.

Advanced segmentation and tracking algorithms

Livecyte revolutionises T-cell killing assays by introducing advanced segmentation and tracking algorithms, enabling the automatic segmentation of target cells and label-free effector T-cells. Through this cutting-edge technology, Livecyte accurately tracks target cells over time, creating unique interaction profiles from the beginning of the experiment until target cell death.

Livecyte’s T-Cell Dashboard view compiles comprehensive metrics based on these interaction profiles, providing an array of information that summarises T-cell cytotoxicity and target cell recognition. Researchers gain a deeper understanding of T-cell-target cell avidity independently from attack potency, yielding greater depth of insight into how T-cells find and kill their targets.

Find out more

You can learn more about the Livecyte and Phasefocus’ new T-cell killing assay by clicking the button below to sign up to their upcoming webinar on Tuesday 19 September.


This site is available in the United States, would you like to view the United States version?

United States Close